An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years

NCT01480674 · clinicaltrials.gov ↗

COMPLETED

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Trastuzumab

Sponsor

Hoffmann-La Roche